Swedish biotech companies have a broad and varied product pipeline that is attracting attention from venture capitalists and pharmaceutical companies.
|Articles|May 2, 2014
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
- Volume 10
- Issue 5
Bristol-Myers Squibb Named First on 2014 Best Corporate Citizens List
Author(s)Melanie Sena
Bristol-Myers Squibb is named No. 1 on 2014 Best Corporate Citizens List for the third time in six years.
Advertisement
The 100 Best Corporate Citizens list ranks companies in the Russell 1000 using nearly 300 data points in seven categories: environment, climate change, employee relations, human rights, governance, finance, and philanthropy.
Source:
Articles in this issue
over 12 years ago
Using eClinical Systems for Supply-Chain Managementover 12 years ago
FDA and Industry Take Action for a More Secure Drug Supply Chainover 12 years ago
Packaging Becomes Enabler for Biopharmaceuticalsover 12 years ago
Azzur Group and BioSPEQ Announce Mergerover 12 years ago
Eli Lilly Launches Second Education Program for Medical Studentsover 12 years ago
Global Instability Impacts Brazil's Pharma Marketover 12 years ago
US Biopharma Worries About Losing Lead in Innovationover 12 years ago
Outsourcing Remains Strong In Traditional Areasover 12 years ago
Process Design Is Critical for Commercial Manufacture of HPAPIsAdvertisement
Related to this article
2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Advertisement
Advertisement